Hikma subsidiary launches palonosetron injection in the US

Hikma Pharmaceuticals announced on Thursday that its wholly-owned US subsidiary West-Ward Pharmaceuticals has launched the palonosetron hydrochloride injection at 0.25mg/2mL.

The FTSE 250 company said West-Ward's palonosetron HCI injection was a serotonin-3 receptor antagonist indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses in both moderately and highly emetogenic cancer chemotherapy.

It said that according to IQVIA, US sales of the palonosetron HCI injection were approximately $447m in the 12 months through to January 2018.

“We are very pleased to add palonosetron HCI injection to our oncology portfolio,” said chief executive of Hikma’s injectables division Riad Mechlaoui.

“The launch of this product further expands our broad Injectables portfolio, bringing value to our customers and patients in the US hospital setting, as well as driving long-term, sustainable growth for our business.”